专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018157232A1 PHARMACEUTICAL COMPOSITIONS 'AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR A1WD USES THEREOF 审中-公开
公开(公告)号：WO2018157232A1
公开(公告)日：2018-09-07
申请号：PCT/CA2018/000039
申请日：2018-02-28
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH
发明人： SADAR, Marianne, D.
IPC分类号： A61K31/225 , A61K31/09 , A61K31/122 , A61K31/166 , A61K31/198 , A61K31/203 , A61K31/353 , A61K31/404 , A61K31/4164 , A61K31/4184 , A61K31/428 , A61K31/454 , A61K31/4545 , A61K31/502 , A61K31/5025 , A61K31/55 , A61K31/551 , A61K38/08 , A61P35/00 , C07C233/65 , C07C237/30 , C07C323/59 , C07C43/23 , C07C69/527 , C07D233/90 , C07D237/32 , C07D401/10 , C07D403/04 , C07D417/12 , C07D471/06 , C07D471/16 , C07D487/04 , C07D487/06 , C07D491/06 , C07K7/00 , C07K7/06
摘要： Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including prostate cancer, are also provided.

2. 发明申请

WO2017177307A1 BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS 审中-公开
标题翻译：双酚衍生物及其作为雄激素受体活性调节剂的应用
公开(公告)号：WO2017177307A1
公开(公告)日：2017-10-19
申请号：PCT/CA2017/000083
申请日：2017-04-18
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH , THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUSTRY LIAISON OFFICE
发明人： ANDERSEN, Raymond , SADAR, Marianne Dorothy , JlAN, Kunzhong , MAWJl, Nasrin R. , WANG, Jun , BANUELOS, Carmen Adriana , YANG, Yu-Chi
IPC分类号： C07C317/16 , A61K31/09 , A61K31/10 , A61K31/165 , A61K31/222 , A61K31/4164 , A61P35/00 , C07C311/04 , C07C317/22 , C07C43/23 , C07D233/60 , C07D295/088
摘要： Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 , R 2 , R 3 , R 11a , R 11b , R 11c , R 11d , and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
摘要翻译：具有式I结构的化合物或其药学上可接受的盐，互变异构体或立体异构体，其中R 1，R 2，R 1，R 3， R 3，R 11b，R 11b，R 11c，R 11d和X，如本文所定义。还提供了这些化合物用于调节雄激素受体活性的用途，癌症和治疗剂中的成像诊断以及治疗有需要的受试者（包括前列腺癌）的方法。

3. 发明申请

WO2017008165A1 CLASSIFICATION METHOD AND TREATMENT FOR ENDOMETRIAL CANCERS 审中-公开
标题翻译：子宫内膜癌的分类方法和治疗
公开(公告)号：WO2017008165A1
公开(公告)日：2017-01-19
申请号：PCT/CA2016/050829
申请日：2016-07-13
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH
发明人： MCALPINE, Jessica , TALHOUK, Aline , HUNTSMAN, David
IPC分类号： G01N33/574 , A61B10/00 , A61B5/00 , A61K45/00
CPC分类号： G01N33/57442 , A61B10/0291 , A61K45/00 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156 , G01N33/6875 , G01N2800/52 , G01N2800/56
摘要： Classification of endometrial cancers by morphologic features is inconsistent, and yields limited prognostic and predictive information. A method of classifying endometrial cancers and treating based on classification comprises obtaining a sample from a subject having endometrial cancer; evaluating the sample for: (a) a hypermutated mismatch repair protein comprising high microsatellite instability phenotype to classify the cancer as: (i) mismatch repair abnormal if present or mismatched repair microsatellite stable if absent; (b) subsequently evaluating the mismatch repair microsatellite stable sample from (a) for a POLE exonuclease domain mutation to classify the cancer as (ii) POLE mutated if present or POLE wild type if absent; and (c) subsequently evaluating the POLE wildtype sample from (b) for a p53 copy number abnormality comprising a high copy number or a low copy number to classify the cancer as (iii) p53 wild type, absent abnormality, and as (iv) p53 abnormal if present.
摘要翻译：通过形态学特征对子宫内膜癌的分类不一致，产生有限的预后和预测信息。分类子宫内膜癌的方法和基于分类的治疗包括从具有子宫内膜癌的受试者获得样品; 评估样品：（a）包含高微卫星不稳定性表型的高度遗传性错配修复蛋白，以将癌症分类为：（i）如果存在错配修复异常或不匹配的修复微卫星如果不存在则稳定; （b）随后评估来自（a）的错配修复微卫星稳定样品，用于POLE核酸外切酶突变以将癌症分类为（ii）如果存在POLE突变或如果不存在则为POLE野生型; 和（c）随后评估来自（b）的包含高拷贝数或低拷贝数的p53拷贝数异常的POLE野生型样品，以将癌症分类为（iii）p53野生型，无异常，以及（iv）如果存在p53异常

4. 发明申请

WO2016000070A1 HYDROPHOBICALLY DERIVATIZED HYPERBRANCHED POLYGLYCEROL FOR INTRAVASCULAR DRUG DELIVERY 审中-公开
标题翻译：用于静脉输送药物的疏水性高分子聚乙烯吡咯烷酮（HYDROPHOBICALLY DERIVATIYED HYPERBRACHED POLYGLYCEROL）
公开(公告)号：WO2016000070A1
公开(公告)日：2016-01-07
申请号：PCT/CA2015/050600
申请日：2015-06-26
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH , THE UNIVERSITY OF BRITISH COLUMBIA , KHAN, Mohamed K. , KIZHAKKEDATHU, Jayachandran N. , MISRI, Ripen , SHENOI, Rajesh A. , WONG, Nelson K. Y. , BROOKS, Donald E.
发明人： KHAN, Mohamed K. , KIZHAKKEDATHU, Jayachandran N. , MISRI, Ripen , SHENOI, Rajesh A. , WONG, Nelson K. Y. , BROOKS, Donald E.
IPC分类号： A61K47/34 , A61K9/51
CPC分类号： A61K9/51 , A61K9/0019 , A61K47/34
摘要： Herein are provided derivatized hyperbranched polyglycerols (HPGs) for use as agents for the delivery of a drug or other biologically active moiety to a target tissue to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation of a pharmaceutical composition for the treatment of indications such cancer. Also provided are derivatized HPGs for use as a pre-treatment or co- treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making derivatized HPGs. In particular embodiments, the HPGs are derivatized with C 10 alkyl chains. Such derivatized HPGs may be suitable for intravascular administration.
摘要翻译：本文提供衍生的超支化聚甘油（HPG），其用作将药物或其它生物活性部分递送至靶组织以治疗诸如癌症的适应症的药剂，其可用于治疗或制造药物，在制备用于治疗这种癌症的适应症的药物组合物中。还提供衍生化的HPG，用作预处理或共处理以改善组织中的药物摄取。此外，还提供了制备衍生化的HPG的方法。在具体实施方案中，HPG用C10烷基链衍生化。这种衍生的HPG可适用于血管内给药。

5. 发明申请

WO2015143558A1 T-CELL EPITOPE IDENTIFICATION 审中-公开
标题翻译： T细胞抗体鉴定
公开(公告)号：WO2015143558A1
公开(公告)日：2015-10-01
申请号：PCT/CA2015/050230
申请日：2015-03-25
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH
发明人： HOLT, Robert , SHARMA, Govinda
IPC分类号： C12Q1/68 , C12N5/10 , C12Q1/02 , C40B30/06 , C40B40/02 , G01N33/567 , C07K14/74
CPC分类号： G01N33/6878 , C12N15/1037 , C12N15/1086 , C12Q1/6886 , C12Q2600/158 , G01N33/5091 , G01N33/56972 , G01N33/6845
摘要： The present invention is a method for determining the identity of the epitopes recognized by T-cells. The method consists of expressing an encoded library of candidate epitope sequences in a recipient reporter cell capable of providing a detectable signal upon cytotoxic attack from a single cognate T-cell followed by contacting the reporter cells with T-cells of interest. The reporter cells with a single indicating cytotoxic attack from a T-cell are isolated and then analyzed by next-generation sequencing in order to identify the epitope sequences. Specifically disclosed is a method in which a library of candidate epitope-encoding nucleic acids are expressed in cells which feature a membrane-bound major histocompatibility complex (MHC) protein, said library produced by transfection of plasmids featuring both a nucleotide encoding the candidate epitope and a nucleotide encoding a FRET-based fluorescent protein cleaved by granzyme.
摘要翻译：本发明是确定由T细胞识别的表位的身份的方法。该方法包括在受体报道细胞中表达候选表位序列的编码文库，其能够在来自单个同源T细胞的细胞毒性攻击后提供可检测信号，随后将报道细胞与感兴趣的T细胞接触。分离具有来自T细胞的单一指示细胞毒性攻击的报道细胞，然后通过下一代测序进行分析，以鉴定表位序列。具体公开了一种方法，其中候选表位编码核酸的文库在具有膜结合主要组织相容性复合物（MHC）蛋白的细胞中表达，所述文库通过转染具有编码候选表位的核苷酸的质粒和编码由颗粒酶切割的基于FRET的荧光蛋白的核苷酸。

6. 发明申请

WO2015085398A1 MATRIPTASE VARIANTS ASSOCIATED WITH TUMORS 审中-公开
标题翻译：与肿瘤相关的MATRIPTASE变量
公开(公告)号：WO2015085398A1
公开(公告)日：2015-06-18
申请号：PCT/CA2014/000875
申请日：2014-12-09
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH , THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT
发明人： JONES, Steven John Mathias , DARGAHI, Daryanaz , BABCOOK, John Stephen
IPC分类号： C12N15/37 , A61K39/395 , A61K47/48 , A61K49/00 , A61P35/00 , C07K16/40 , C07K16/46 , C12N9/64 , C12Q1/68 , G01N33/48 , G01N33/574
CPC分类号： G01N33/57449 , C12N9/6421 , C12Q1/68 , C12Q1/6886 , C12Q2600/156 , G01N33/57415 , G01N33/57423 , G01N33/57434
摘要： Described are variants of matriptase that are associated with cancer. The variants encode polypeptides that are missing all or part of an LDLRA1 domain and/or all or part of a LDLRA3 domain. Also described are binding agents such as antibodies that are selective for the variant matriptase polypeptides as well as conjugates thereof. The binding proteins and conjugates are useful for the identification of cancer cells or for the treatment of cancer.
摘要翻译：描述了与癌症相关的matriptase的变体。该变体编码缺失LDLRA1结构域和/或全部或部分LDLRA3结构域的全部或部分的多肽。还描述了对变体matriptase多肽及其缀合物具有选择性的结合剂，例如抗体。结合蛋白和结合物可用于鉴定癌细胞或治疗癌症。

7. 发明申请

WO2015069790A1 METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS EXPRESSION PROFILING 审中-公开
标题翻译：通过手段表达式分类淋巴细胞类型的方法
公开(公告)号：WO2015069790A1
公开(公告)日：2015-05-14
申请号：PCT/US2014/064161
申请日：2014-11-05
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , BRITISH COLUMBIA CANCER AGENCY BRANCH , ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVIERSITY OF ARIZONA , UNIVERSITAT DE BARCELONA , HOSPITAL CLINIC DE BARCELONA , CLEVELAND CLINIC , BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA , OREGON HEALTH & SCIENCE UNIVERSITY , JULIUS-MAXIMILIANS-UNIVERSITY OF WUERZBURG , OSLO UNIVERSITY HOSPITAL HF
发明人： STAUDT, Louis M. , WRIGHT, George W. , SCOTT, David William , CONNORS, Joseph M. , GASCOYNE, Randy D. , RIMSZA, Lisa , CAMPO GUERRI, Elias , GREINER, Timothy C. , COOK, James Robert , FU, Kai , WILLIAMS, Paul Michael , LIH, Chih-Jian , JAFFE, Elaine S. , BRAZIEL, Rita M. , ROSENWALD, Andreas , SMELAND, Erlend B. , CHAN, Wing C. , OTT, German , DELABIE, Jan , WEISENBURGER, Dennis
IPC分类号： C12Q1/68
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Q2600/166 , G06F19/12
摘要： The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
摘要翻译：本发明涉及用于选择活化的B细胞样弥漫性大B细胞淋巴瘤（ABC DLBCL）受试者，生发中心B细胞样弥漫性大B细胞淋巴瘤（GCB DLBCL）受试者，原发性纵隔 B细胞淋巴瘤（PMBL）受试者，伯基特淋巴瘤（BL）受试者或套细胞淋巴瘤（MCL）受试者，通过分析从受试者获得的数字基因表达数据，例如来自活组织检查样品。

8. 发明申请

WO2013177245A3 NANO46 GENES AND METHODS TO PREDICT BREAST CANCER OUTCOME 审中-公开
标题翻译： NANO46预测乳腺癌的基因和方法
公开(公告)号：WO2013177245A3
公开(公告)日：2015-01-29
申请号：PCT/US2013042157
申请日：2013-05-22
申请人： NANOSTRING TECHNOLOGIES INC , UNIV NORTH CAROLINA , UNIV UTAH RES FOUND , BRITISH COLUMBIA CANCER AGENCY , UNIV WASHINGTON
发明人： FERREE SEAN M , STORHOFF JAMES JUSTIN , PARKER JOEL S , PEROU CHARLES M , ELLIS MATTHEW J , BERNARD PHILIP S , NIELSEN TORSTEN O
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.
摘要翻译：本发明提供了分类和评估具有乳腺癌的受试者的预后的方法。这些方法包括使用训练为基于乳腺癌内在亚型分层受试者的监督算法来预测乳腺癌亚型。该预测模型基于表1中列出的内在基因的基因表达谱。进一步提供了用于预测诊断患有或怀疑患有乳腺癌的受试者的结果或对治疗的反应的组合物和方法。这些方法可用于指导或确定患有乳腺癌的受试者的治疗方案。本发明的方法还包括用于评价基因表达谱（包括微阵列和定量聚合酶链反应测定）的方法，以及包含用于实施本发明方法的试剂的试剂盒。

9. 发明申请

WO2014205555A8 METHODS AND USES FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER 审中-公开
公开(公告)号：WO2014205555A8
公开(公告)日：2014-12-31
申请号：PCT/CA2014/000538
申请日：2014-06-27
申请人： BRITISH COLUMBIA CANCER AGENCY BRANCH
发明人： HELGASON, Cheryl D. , CREA, Francesco , WANG, Yuzhuo , CHI, Kim N. , WATAHIKI, Akira , LIU, Hui Hsuan , PAROLIA, Abhijit
IPC分类号： A61K31/713 , A61K31/7088 , A61P35/00 , C12Q1/68 , G01N33/48 , G01N33/50 , C12N15/113
摘要： In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment monitoring of prostate cancer (PCa) in a subject. In another aspect, methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous prostate cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (IncRNA), whose expression is significantly altered in biological samples obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to prostate tissue and is elevated in both cancerous prostate tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of cancer.

10. 发明申请

WO2014124537A1 METHOD AND APPARATUS FOR OPTICAL MEASUREMENTS UNDER AMBIENT LIGHT CONDITIONS 审中-公开
标题翻译：光环境条件下光学测量的方法与装置
公开(公告)号：WO2014124537A1
公开(公告)日：2014-08-21
申请号：PCT/CA2014/050100
申请日：2014-02-14
申请人： VERISANTE TECHNOLOGY, INC. , BRITISH COLUMBIA CANCER AGENCY BRANCH
发明人： ZENG, Haishan , ZHAO, Jianhua , SHORT, Michael , BRAUN, Thomas Andrew
IPC分类号： G01J3/02 , A61B6/00 , F21V33/00
CPC分类号： A61B5/0071 , A61B5/0075 , A61B5/742 , A61B2560/0247 , F21K9/60 , G01J3/10 , G01J3/44 , G01J2003/104
摘要： Examples of a spectroscopy system with a specially design ambient illumination system are disclosed. The ambient illumination system comprises one or more light emitting diodes (LEDs) that provide illumination light in the wavelength of 400 - 785 nm. The ambient illumination system can further comprise a filter to block light above 785nm. The filter can be placed directly in front of LED emitters. The LEDs can be white LEDs or RGB LEDs. The spectroscopy system can further comprise a control system that can receive a signal from the spectral probe when the spectral measurements commence and can instantaneously send a signal to automatically switch off the ambient illumination system and to receive a signal from the spectral probe when the spectral measurements are terminated and automatically switch on the ambient illumination system. Examples of methods of operating the spectroscopy system and the ambient illumination system are disclosed.
摘要翻译：公开了具有特别设计的环境照明系统的光谱系统的实例。环境照明系统包括提供400-785nm波长的照明光的一个或多个发光二极管（LED）。环境照明系统还可以包括用于阻挡高于785nm的光的滤光器。滤波器可以直接放在LED发射器的前面。 LED可以是白色LED或RGB LED。光谱系统还可以包括一个控制系统，当光谱测量开始时可以从光谱探测器接收信号，并且可以瞬时发送一个信号以自动切断环境照明系统，并在光谱测量时接收来自光谱探测器的信号被终止并自动打开环境照明系统。公开了操作光谱系统和环境照明系统的方法的实例。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式